Clinical observation of Shenluoan Decoction for treating obese patients with early diabetic nephropathy / 中草药

ABSTRACT

Objective: To observe the therapeutic effects and possible mechanism of Shenluoan Decoction on the obese patients with early diabetic nephropathy. Methods: Obese patients with early diabetic nephropathy (106 cases) were randomly assigned into control group (n = 53, treated by Irbesartan) and treatment group (n = 53, treated by Shenluoan Decoction combined with Irbesartan), and the conventional Western therapy was given to all the patients in both groups. The changes of therapeutic efficacy, Chinese medicine syndrome, such as waistline, serum creatinine (SCr), blood urea nitrogen (BUN), total cholesterol (TC), triglyeride (TG), fasting blood glucose (FBG), urinary podocalyxin (PCX), urinary nephrin, urinary albumin, and urine creatinine were detected before and after 6 months treatment. Results: The experiment was completed with 102 cases. The total effective rate in the treatment group (90.00%) was significantly higher than that of control group (67.31%) (P 0.05). After the treatment, the levels of SCr, TC, and TG were reduced significantly in the treatment group (P < 0.05), and showed significant difference compared with those in the control group (P < 0.05). The levels of UPCX/UCR, UNephrin/UCR, and UACR were decreased with significant differences compared with those before treatment and in the control group, respectively (P < 0.05). UPCX/UCR, UNephrin/UCR, and UACR showed positive correlation. Conclusion: The combination of Shenluoan Decoction and Irbesartan has a better effect than the single use of Irbesartan on the obese patients with early diabetic nephropathy. Its mechanism may be related to providing some renal protection and reducing the PCX and nephrin excretion.